Mer­ck de­tails PhII TIG­IT/PD-1 fail in lung can­cer

Nine months af­ter re­veal­ing that its TIG­IT/PD-1 com­bo failed a mid-stage lung can­cer study, Mer­ck is spelling out the full re­sults — with the com­bo miss­ing all the pri­ma­ry and sec­ondary end­points.

De­spite the flop, Mer­ck kept go­ing with a slate of Phase III stud­ies it had al­ready launched for the can­di­date, a co­for­mu­la­tion of vi­bostolimab — Mer­ck’s TIG­IT an­ti­body — and its star check­point drug Keytru­da. The first read­out for these stud­ies is ex­pect­ed to ar­rive in 2025, and the com­pa­ny said the da­ta from the Phase II KeyVibe-002 tri­al will in­form the pro­gram.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER